Access to Innovative and Curative Therapies
November 5-7, 2020
Accès aux thérapies novatrices et curatives
Du 5 au 7 novembre 2020
Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients?
What can patient groups do to ensure access to innovative and curative therapies?
These questions will be explored over two days of interactive and engaging sessions.
De nombreuses thérapies novatrices et curatives arrivent sur le marché pour des troubles sanguins rares, mais est-ce que les patient-es canadien-nes y auront accès?
Que peuvent faire les groupes de patients pour veiller à l’accessibilité aux thérapies novatrices et curatives?
Nous aborderons ces questions pendant deux jours de captivantes séances interactives.
November 5: Innovative Therapies (12pm-3pm ET)
12:00 Welcome, Introductions and Land Acknowledgement
12:10 Keynote: A New Era of Personalized Healthcare
Michael Duong, Director of Personalized Healthcare, Roche Canada
12:30 Session 1: Introduction to novel therapy types: Gene therapies, RNAis, Monoclonal antibodies
Discussion: How might these novel therapies impact the burden of illness and associated direct and indirect costs?
1:30 Break (Lobby Chat Room available)
1:50 Session 2: Groundbreaking trials, domestic and international
Discussion: What is the role of clinical trials in access to innovative therapies? How do they allow us to gain access, and what happens to our access once the trial ends? Are Canadian Centres of Excellence sufficiently represented in clinical trials for groundbreaking therapies? If not, why not?
2:50 Day Wrap Up
3:00 Adjourn for the day
November 6: Innovative Access (12pm-3pm ET)
12:00 Welcome back and recap
Erin Harder, Chair, NRBDO
12:10 Keynote: Accessing innovative and curative therapies
Fred Horne, Public Advisor, 3Sixty Public Affairs
12:30 Session 3: What needs to happen for innovative and curative therapies to be accessible to Canadian patients?
Discussion: Does the patient perspective currently receive the weight it deserves in new product reviews? How can HTA bodies and patient organizations work together to ensure more genuine engagement?
1:30 Break (Chat Room available)
1:50 Session 4: What needs to happen for innovative and curative therapies to be accessible to Canadian patients?
Supply and Distribution Perspectives:
Discussion: What role can patient groups play in realizing these changes discussed today?
2:50 Day Wrap Up
3:00 Conference Adjourned
Day 3: NRBDO Members Meeting - member group representatives only